rts logo

Halozyme Therapeutics Inc. (HALO) Review – Making Smarter Decisions

Halozyme Therapeutics Inc. (NASDAQ: HALO) is 43.29% higher on its value in year-to-date trading and has touched a low of $32.83 and a high of $54.35 in the current 52-week trading range. The question becomes, what are the chances the stock will continue to grow shareholders’ wealth in the market. Here’s what analysts think will happen to its price in the coming time. The HALO stock was last observed hovering at around $52.88 in the last trading session, with the day’s gains setting it 0.08%.

Currently trading at $52.96, the stock is 3.34% and 13.73% above its SMA20 and SMA50 respectively. However, with a daily trading volume of 1.59 million and changing 0.15% at the moment leaves the stock 32.28% off its SMA200. HALO registered 41.91% gain for a year compared to 6-month gain of 49.14%.

3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.

We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.

Click here for full details and to join for free
Sponsored

The stock witnessed a 4.15% loss in the last 1 month and extending the period to 3 months gives it a 31.97%, and is 3.24% up over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 2.87% over the week and 2.84% over the month.

Halozyme Therapeutics Inc. (HALO) has around 373 employees, a market worth around $6.74B and $862.99M in sales. Current P/E ratio is 21.90 and Fwd P/E is 11.00. Profit margin for the company is 36.94%. Distance from 52-week low is 61.32% and -2.56% from its 52-week high. The company has generated returns on investments over the last 12 months (18.99%).

The EPS is expected to grow by 40.07% this year

The shares outstanding are 126.77M, and float is at 125.88M with Short Float at 7.39%.

Halozyme Therapeutics Inc. (HALO) Insider Activity

The most recent transaction is an insider sale by LaBrosse Nicole, the company’s SVP, CHIEF FINANCIAL OFFICER. SEC filings show that LaBrosse Nicole sold 10,000 shares of the company’s common stock on Jun 28 ’24 at a price of $52.04 per share for a total of $0.52 million. Following the sale, the insider now owns 15480.0 shares.

Halozyme Therapeutics Inc. disclosed in a document filed with the SEC on Jun 27 ’24 that LaBrosse Nicole (SVP, CHIEF FINANCIAL OFFICER) sold a total of 10,000 shares of the company’s common stock. The trade occurred on Jun 27 ’24 and was made at $51.93 per share for $0.52 million. Following the transaction, the insider now directly holds 15480.0 shares of the HALO stock.

Still, SEC filings show that on Jun 26 ’24, LaBrosse Nicole (SVP, CHIEF FINANCIAL OFFICER) disposed off 10,000 shares at an average price of $51.82 for $0.52 million. The insider now directly holds 15,480 shares of Halozyme Therapeutics Inc. (HALO).

Related Posts